The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level

International Journal of Cardiology

Volumn 109, Issue 1, 2006, Pages 48-52

  Tousoulis, Dimitris ^a   Antoniades, Charalambos ^a   Katsi, Vasiliki ^a   Bosinakou, Erini ^a   Kotsopoulou, Maria ^a   Tsioufis, Costas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Inflammation; Statins; Thrombosis; Unstable angina

Indexed keywords

ATORVASTATIN; CHOLESTEROL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; LABORATORY TEST; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CHEMOKINE CCL2; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 33645382878     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.05.055     Document Type: Article

References (32)

1. The 4S Investigators Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level N Engl J Med 335 1996 1001 1009
3. The LIPID Investigators Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
4. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
5. P.M. Ridker, J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women Circulation 98 1998 731 733
6. R.S. Blumenthal Statins: effective antiatherosclerotic therapy Am Heart J 139 2000 577 583
7. J. Dupuis, J.C. Tardif, P. Cernacek, and P. Theroux Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of endothelium) trial Circulation 99 1999 3227 3233
8. E.S. Stroes, H.A. Koomans, T.W. de Bruin, and T.J. Rabelink Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication Lancet 346 1995 457 471
9. C.B. Treasure, J.L. Klein, W.S. Weintraub, J.D. Talley, M.E. Stillabower, and A.S. Kosinski Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease N Engl J Med 332 1995 481 487
10. K.A. Mitropoulos Lipids-thrombosis interface Br Med Bull 50 1994 813 832
11. R.S. Rosnenson, C.C. Tangney, and L.C. Casey Inhibition of proinflammatory cytokine production by pravastatin Lancet 353 1999 983 984
12. O. Grip, S. Janciauskiene, and S. Lindgren Pravastatin down-regulates inflammatory mediators in human monocytes in vitro Eur J Pharmacol 410 2000 83 92
13. M. Romano, A. Mezzetti, C. Marulli, G. Ciabattoni, F. Febo, and S. Di Ienno Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide J Investig Med 48 2000 183 189
14. E. Braunwald, E.M. Antman, J.W. Beasley, R.M. Califf, M.D. Cheitlin, J.S. Hochman American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina ACC/AHA guidelines for the management of patients with unstable angina non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) J Am Coll Cardiol 36 2000 970 1062
15. K. Koh Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability Cardiovasc Res 47 2000 648 657
16. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction of C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolaemia Circulation 103 2001 1191 1193
17. P.M. Ridker, N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
18. Y.C. Doo, S.J. Han, J.H. Lee, G.Y. Cho, K.S. Hong, and K.R. Han Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris Am J Cardiol 93 5 2004 554 558
19. R. Schiele, A.K. Gitt, and T. Heer Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of Mitra-2 Circulation 102 suppl 2000 II 435
20. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, and R.A. Vogel Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
21. L.C. Correia, A.C. Sposito, J.C. Lima, L.P. Magalhaes, L.C. Passos, and M.S. Rocha Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction Am J Cardiol 92 2003 298 301
22. H.D. Aronow, E.J. Topol, M.T. Roe, P.L. Houghtaling, K.E. Wolski, and A.M. Lincoff Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study Lancet 357 2001 1063 1068
23. L.K. Newby, A. Kristinsson, M.V. Bhapkar, P.E. Aylward, A.P. Dimas, and W.W. Klein Sibrafiban vs aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Early statin initiation and outcomes in patients with acute coronary syndromes JAMA 287 2002 3087 3095
24. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
25. S. Kinlay, G.G. Schwartz, A.G. Olsson, N. Rifai, S.J. Leslie, W.J. Sasiela Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566
26. The MIRACL Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.The MIRACL study JAMA 285 2001 1711 1718
27. S. Okazaki, T. Yokoyama, K. Miyauchi, K. Shimada, T. Kurata, and H. Sato Early statin treatment in patients with acute coronary syndrome Circulation 110 2004 1061 1068
28. P.O. Bonetti, L.O. Lerman, C. Napoli, and A. Lerman Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 24 3 2003 225 248
29. D. Li, H. Chen, F. Romeo, T. Sawamura, T. Saldeen, and J.L. Mehta Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1 J Pharmacol Exp Ther 302 2 2002 601 605
30. M. Ortego, C. Bustos, M.A. Hernandez-Presa, J. Tunon, C. Diaz, and G. Hernandez Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells Atherosclerosis 147 2 1999 253 261
31. R. Terkeltaub, J. Solan, M. Barry, D. Santoro, and G.M. Bokoch Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells J Leukoc Biol 55 1994 749 755
32. R. Rosenson, C. Tangney, D. Levine, T. Parker, and B. Gordon Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects J Lab Clin Med 145 2005 83 87